Sandsdal, Rasmus M.
Juhl, Christian R.
Jensen, Simon B. K.
Lundgren, Julie R.
Janus, Charlotte
Blond, Martin B.
Rosenkilde, Mads
Bogh, Adrian F.
Gliemann, Lasse
Jensen, Jens-Erik B.
Antoniades, Charalambos
Stallknecht, Bente M.
Holst, Jens J.
Madsbad, Sten
Torekov, Signe S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
https://doi.org/10.1186/s12933-023-01765-z
Funding for this research was provided by:
Novo Nordisk Fonden (NNF15SA0018346)
Helsefonden
Novo Nordisk
Article History
Received: 4 October 2022
Accepted: 3 February 2023
First Online: 25 February 2023
Declarations
:
: The trial was approved by the Committee of Health Research Ethics (H-16027082) and the Danish Medicines Agency (EudraCT: 2015-005585-32) and was conducted according to the Declaration of Helsinki and ICH Good Clinical Practice guidelines. Participants provided written informed consent before inclusion.
: Not applicable.
: RMS: Family member holds Novo Nordisk stocks. MR: Currently employed at Novo Nordisk. JJH: Advisory boards: Novo Nordisk. SM: Advisory boards: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. Lecture fees: AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. Grant Recipient: Novo Nordisk, Boehringer-Ingelheim. SST: Grant and lecture fee recipient, Novo Nordisk. JRL, CJ, CRJ, SBKJ, MBB, AFB, LG, JBJ, CA, BMS have no disclosures.